Looking at top Wall Street opinions, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) has recently made its way into the research list of Cantor Fitzgerald – signaling that their analyst’s rating adjustment is noteworthy. This stock was Overweight in the eyes of Cantor Fitzgerald, as reported on Friday, September 21st, 2018. Another heavy-hitting research note was published by Piper Jaffray on Friday September 7th, 2018, with this firm Resumed CPRX to an updated rating of Overweight. In the past six months and three months of trading, shares of Catalyst Pharmaceuticals, Inc. (CPRX) have moved by 22.92% and 31.60%, respectively.
Brokerage Updates Related to Catalyst Pharmaceuticals, Inc. (CPRX) Stock
Not a Single analyst have given underperform rating or sell rating, and 1 have given a rating of Buy or better. Based on the 6 stock market experts following this company, the average 12-month price target is $8.58. Moreover, individual price targets range between $4.50-$10.00. With its recent move to $9.00, we can see that these firms project this stock will gain by 6.63% in one year.
Updates from Catalyst Pharmaceuticals, Inc. (CPRX) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 5.40% rise since the beginning of the calendar year. A Director at Catalyst Pharmaceuticals, Inc. (CPRX) bought some of its shares in a transaction that was finalized on Dec 27. Similarly, MCENANY PATRICK J bought 20,000 shares of the organization’s stock at $2.24 apiece and racked up $44,800 in earnings from the purchase. Now, MCENANY PATRICK J holds 4,737,693 shares of the company following the exchange. A Director of the organization named O’Keeffe Charles B, was engaged in a transaction that occurred on Dec 14 that managed to be worth $50,000 from the purchase of 20,000 common shares at a price of $2.50 per individual share.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Results in the Pipeline
The next scheduled release of financial results for Catalyst Pharmaceuticals, Inc. will be for the Mar-19 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be -$0.13. In the same vein, they expect sales for the quarter to amount to $1.60 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $12.45 million in revenue alongside EPS at -$0.01. On average, the analyst projection was calling for $0.50 million with -$0.14 per share in earnings, respectively.
FireEye, Inc. (NASDAQ:FEYE) experienced a drop of -0.45% from the closing price in the previous trading day. That drove the price to $15.50 per share, as observed on December 31st, 1969, at a time when the total trading volume reached 4,139,166 shares of stock – compared to the typical average of 3.37M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $20.00.
Pricing Indications for FireEye, Inc. (FEYE)
This organization has had a price-to-earnings ratio of in the last year. Meanwhile, it gained 16.30 from its observable 50-day simple moving average. Right at this moment, the per-share value is -7.87% lower than the mean per-share price over the last 200 days in the market.
FireEye, Inc. (NASDAQ:FEYE) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 6 have a Buy rating, 6 have an outperform rating, while 13 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.30, based on information from Thomson Reuters.
FEYE Stock Value Potential
In trading activity as of late, this stock’s value was 16.82 up from its 200 day moving average, while also -4.98% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $17.00-$27.00. The market value for the entire organization reached 3.16B. In the last trading session, the price ended the day at $15.57. The institutional holdings related to this organization account for 2.80%, and the Beta factor is now 0.95. This company’s RSI (Relative Strength Index) managed to hit 40.98.
FireEye, Inc. (NASDAQ:FEYE) Analyst Points of Focus
FireEye, Inc. (FEYE) has found itself inside of Mizuho’s research list, so their analyst rating adjustment is worth taking note of. This stock was Initiated to Neutral, by Mizuho, as garnered from a news report on Wednesday March 27th, 2019. An additional helpful research note was sent out by JP Morgan’s on Monday March 11th, 2019. The brokerage decided to upgrade FEYE to Overweight from its previous rating of Neutral.